ZVSA — Zyversa Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity
Brief: Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation
Brief: ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status
Brief: Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Zyversa Therapeutics Highlights Published Data Demonstrating That Obesity Results In Neuroinflammation Implicated In Development Of Neurodegenerative Diseases
Brief: ZyVersa Therapeutics Expect To File IND For IC 100 In Q2 2025
Zyversa Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Zyversa Therapeutics Inc expected to post a loss of $3.70 a share - Earnings Preview
Brief: Zyversa Therapeutics On Feb 29, Got Nasdaq Approval To Transfer Listing Of Co’S Common Stock From Nasdaq Global Market To Nasdaq Capital Market
Brief: ZyVersa Therapeutics Publishes New White Paper
Brief: Zyversa Therapeutics CEO Issues Letter To Shareholders Providing Outlook For 2024
Brief: Zyversa Therapeutics Announces Pricing Of $5 Mln Public Offering
Brief: Zyversa Therapeutics Announces Reverse Stock Split & Increase In Authorized Shares Of Common Stock
U.S. STOCKS ON THE MOVE-Broadcom, FedEx, Wheels Up Experience
Brief: Zyversa Therapeutics Inc Says Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
Brief: Zyversa Therapeutics Reports Second Quarter 2023 Corporate And Financial Results
Brief: Zyversa Therapeutics Announces Pricing Of $2.1 Million Public Offering
Brief: European Patent Granted For ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator Var 200 For Use In Patients With Diabetic Nephropathy/Diabetic Kidney Disease
Brief: ZyVersa Therapeutics - Expect To Complete Preclinical Program For IC 100 By Year's End